Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.

OBJECTIVE To assess the efficacy of low-dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). METHODS At the start of their initial treatment with a disease-modifying antirheumatic drug (DMARD), patients with early (duration < or =1 year) active RA were randomly assigned to receive either 7.5 mg/day prednisolone or no prednisolone for 2 years. Radiographs of the hands and feet were obtained at baseline and after 1 and 2 years and scored according to the Sharp score as modified by van der Heijde. Remission was defined as a Disease Activity Score in 28 joints of <2.6. Bone mineral density was measured by dual x-ray absorptiometry at baseline and after 2 years. RESULTS Of the 250 patients included, 242 completed the study and 225 had radiographs available both at baseline and at 2 years. At 2 years, the median and interquartile range (IQR) change in total Sharp score was lower in the prednisolone group than in the no-prednisolone group (1.8 [IQR 0.5-6.0] versus 3.5 [IQR 0.5-10]; P = 0.019). In the prednisolone group, there were fewer newly eroded joints per patient after 2 years (median 0.5 [IQR 0-2] versus 1.25 [IQR 0-3.25]; P = 0.007). In the prednisolone group, 25.9% of patients had radiographic progression beyond the smallest detectable difference compared with 39.3% of patients in the no-prednisolone group (P = 0.033). At 2 years, 55.5% of patients in the prednisolone group had achieved disease remission, compared with 32.8% of patients in the no-prednisolone group (P = 0.0005). There were few adverse events that led to withdrawal. Bone loss during the 2-year study was similar in the 2 treatment groups. CONCLUSION Prednisolone at 7.5 mg/day added to the initial DMARD retarded the progression of radiographic damage after 2 years in patients with early RA, provided a high remission rate, and was well tolerated. Therefore, the data support the use of low-dose prednisolone as an adjunct to DMARDs in early active RA.

[1]  M. Boers,et al.  Glucocorticoids in the treatment of early and late RA , 2003, Annals of the rheumatic diseases.

[2]  D. M. van der Heijde,et al.  Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. , 2004, Arthritis and rheumatism.

[3]  C. Ekdahl,et al.  Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. , 1988, Scandinavian journal of rheumatology.

[4]  B. Svensson,et al.  Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. , 2000, Rheumatology.

[5]  M. Dougados,et al.  Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study , 2003, Annals of the rheumatic diseases.

[6]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[7]  J. Pødenphant,et al.  A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects , 1999, Annals of the rheumatic diseases.

[8]  M. V. van Leeuwen,et al.  Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. , 1997, The Journal of rheumatology.

[9]  S. van der Linden,et al.  Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change , 2004, Annals of the rheumatic diseases.

[10]  L. Criswell,et al.  Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. , 1996, Arthritis and rheumatism.

[11]  D. Symmons,et al.  Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. , 1998, The Journal of rheumatology.

[12]  M. Prevoo,et al.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.

[13]  J. Jacobs,et al.  Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2002, Annals of Internal Medicine.

[14]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[15]  J. Kirwan,et al.  Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. , 1998, British journal of rheumatology.

[16]  Maarten Boers,et al.  The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. , 2004, Arthritis and rheumatism.

[17]  A Woolf,et al.  The links between joint damage and disability in rheumatoid arthritis. , 2000, Rheumatology.

[18]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.

[19]  M. Suarez‐Almazor,et al.  Moderate-term, low-dose corticosteroids for rheumatoid arthritis. , 1998, The Cochrane database of systematic reviews.

[20]  R. Rau,et al.  Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis – , 2000, Zeitschrift für Rheumatologie.

[21]  B. Bresnihan,et al.  Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. , 1996, British journal of rheumatology.

[22]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[23]  S. van der Linden,et al.  Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[24]  R. Madhok,et al.  Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial , 2004, Annals of the rheumatic diseases.

[25]  J. Kirwan,et al.  The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. , 1995, The New England journal of medicine.

[26]  K. Eberhardt,et al.  Functional assessment of early rheumatoid arthritis. , 1988, British journal of rheumatology.

[27]  T. Pincus,et al.  Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[28]  H. Genant,et al.  Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. , 2000, The Journal of rheumatology.

[29]  S. van der Linden,et al.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis , 1997, The Lancet.

[30]  L. Moreland,et al.  Glucocorticoids and rheumatoid arthritis: back to the future? , 2002, Arthritis and rheumatism.

[31]  Rene Westhovens,et al.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. , 2002, Arthritis and rheumatism.

[32]  M. Boers,et al.  Low dose prednisolone for treatment of RA. , 2004, Annals of the rheumatic diseases.

[33]  J. Jacobs,et al.  The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. , 2004, Arthritis and rheumatism.

[34]  J. Kirwan.  The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. , 2004, Arthritis and rheumatism.

[35]  I. Hafström,et al.  Bone mineral density in women and men with early rheumatoid arthritis. , 2001, Scandinavian journal of rheumatology.

[36]  R. Palmer,et al.  A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[37]  J. O'dell,et al.  Treating rheumatoid arthritis early: a window of opportunity? , 2002, Arthritis and rheumatism.

[38]  M. A. van 't Hof,et al.  Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[39]  M. Boers.  The case for corticosteroids in the treatment of early rheumatoid arthritis. , 1999, Rheumatology.

[40]  P. Hench,et al.  The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. , 1949, Proceedings of the staff meetings. Mayo Clinic.

[41]  P. Gøtzsche,et al.  Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis , 1998, BMJ.

[42]  A. Newberg,et al.  Low dose prednisone therapy in rheumatoid arthritis: a double blind study. , 1983, The Journal of rheumatology.

[43]  S. van der Linden,et al.  Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. , 1999, Rheumatology.